-
The 8th National Hematology Conference, facing the lymphoma hematopoietic stem cell transplant application dilemma, how can blood doctors break the situation?
Time of Update: 2020-11-06
In China, data from Beijing Cancer Hospital show a five-year survival rate of 62%, close to the level of developed countries in Europe and the United States, mainly due to two aspects: first, the establishment and continuous improvement of the norms, including hematopoietic stem cell transplantation, overall treatment strategy, and second, a number of new drug clinical trials.
-
Blood: PD-1 and MAPK double inhibition "hand in hand" to overcome LCH's T-cell depletion
Time of Update: 2020-11-06
T lymphocytes in the LCH micro-environment showed "fatigue" esogram CD8 plus and CD4 plus T cells both showed "fatigue" espressoes with high expression of immune checkpoint subjects.
-
Japanese blood this harmful substance exceeds the standard! Suspected U.S. troops "poisoned"?
Time of Update: 2020-11-06
Not long ago reported that the Japanese government plans to discharge 300,000 tons of nuclear waste water into the Pacific Ocean, today there is news that some residents of Tokyo, Japan, because of the intake of contaminated water, resulting in the blood of harmful substances exceeded the standard, it is surprising that the source of pollution may be the U.
-
Early symptoms of leukemia are too "common", many parents do not pay attention to, the result is bitter children!
Time of Update: 2020-11-06
is often used in industry, but benzene is a class of carcinogens that can damage bone marrow, causing chromosomal distortion, long-term exposure to benzene and benzene products will increase the likelihood of leukemia.
-
Blood: Genome-wide transcriptional mapping and RNA sequencing of cytoplography and iPSC-sourced macrocytes
Time of Update: 2020-11-04
summary, this study analyzed the regulatory characteristics of MKs and plateplates, which overlap significantly in gene expression, detected eQTL, and the richness of known super-enhancers in the n- and sub-regions associated with plate plateboard biology.
-
Application for the first clinical trial of gene editing therapy in China accepted
Time of Update: 2020-11-04
On October 27th, Boya announced that the Drug Review Center of the State Drug Administration had accepted its clinical trial application for a gene-editing therapy product for transfusion-dependent β thalassemia, ET-01, or CRISPR/Cas9 gene-modified self-made CD34 plus hematocyte injection of BCL11A red line enhancers.
-
JAMA Intern Med: Treatment options for severe symptomatic hyponatrexemia - chronic persistent infusion vs intermittent single quick injection
Time of Update: 2020-11-04
High seepage saline is the main method for treating severe symptomatic hyponatrea, which can be divided into chronic persistent infusion (SCI) or intermittent single rapid injection (RIB) therapy, and researchers recently compared the differences in the risk of over-correction of high permeable saline RIB and SCI in patients with symptomatic hyponatreaemia.
-
J Clin Oncol: Evtini combined with Azatide to treat newly diagnosed acute myeloid leukemia
Time of Update: 2020-11-04
15.1 months of remission and changes in IDH1 mutation status during treatment, and as of February 19, 2019, 10 patients continued treatment.
is thorough and long-lasting, and most patients with complete remission can achieve mIDH1 mutation removal.
-
Take stock: A selection of Blod research on October 29, 2020
Time of Update: 2020-11-04
2: The clinical success of butinib's treatment of Fahrenheit globulinemia Phase II https://doi.org/10.1182/blood.2020006449 Fahrenheit jumboglobulinemia (WM) ), a rare non-Hodgkin's lymphoma, lymphocyte lymphoma, the patient manifests as mouth and nose haemorrhage, anemia, decreased levels of fibrinogen in the blood, swollen lymph nodes, a large number of proliferating plasma cells in the bone marrow, and due to a large increase in globulin caused by blood viscosity.
-
Lancet Oncol: Venetoclax combined boronitazome and dexemisen significantly improved prognosis in patients with relapsed/reassotic multiple myeloma
Time of Update: 2020-11-04
study was a randomized, double-blind, multicenter Phase 3 trial that recruited patients with recurring/refrectable multiple myeloma over the age of 18 to be randomly assigned to the experimental group (Venetoclax combined boronazome and dexemisen) or the placebo group (placebo combined boronitazome and dexamison) at 2:1.
-
Blood: Prognosis and biomarker assessment of vascular ococcytosis of sickle cell disease
Time of Update: 2020-11-04
reported 114 VOC events and 346 VOC days, of which 62.3% and 78.3% were self-treated at home.
In summary, the study showed that in SCD-related clinical trials, patient-reported VOC days were used as a potential endpoint to accurately monitor out-of-hospital pain;
-
Blood: Isatuximab ± treatment of relapse/reassoilable multiple myeloma
Time of Update: 2020-11-04
in general, Isatuximab combined with Symesong treatment improved the remission and survival rates of patients with relapsed/resuscable multiple myeloma without significant adverse reactions.
-
2020 CCO China Oncology Conference. Huang Xiaojun: Precision treatment of leukemia - China's program, the world shared.
Time of Update: 2020-10-28
The above series of work breaks through the "clinical exclusion zone" of single-fold combination transplantation, creates a new model of treatment of blood diseases - "Beijing Program", basically solves the world problem of lack of sources of hematopoietic stem cell transplantation, and leads the world into a new era of supply for all.
-
J Clin Oncol: Characteristics of recurrence after initial remission in patients with early classic Hodgkin's lymphoma.
Time of Update: 2020-10-27
Moccia and others assessed the disease and treatment characteristics of patients with early-stage typical Hodgkin's lymphoma (ES-HL) recurrence after first-line risk adaptation, comparing second-line therapy, high-dose chemotherapy, autobiographical stem cell transplantation (ASCT) and conventional chemotherapy (CTx).
-
Blood: Effect of HLA table antigen mis pairing of plate plate plates.
Time of Update: 2020-10-27
the study was a randomized, double-blind, non-disadvantaged, cross-test designed to compare the prognosis of plateplates infused with HLA table matching (HEM) and plateplates with HLA standard antigen matching (HSM).
therefore, HLA isoimmune patients should as far as possible infusion of table antigen-matched plateplates.
-
BCL-2 inhibitor Venetoclax is fully approved by the FDA for the treatment of acute myeloid leukemia (AML)
Time of Update: 2020-10-27
Recently, the FDA has approved a combination of Venetoclax with azatsin, tesitalbin, or low-dose LDAC for the treatment of patients over 75 years of age with acute myeloid leukemia (AML), who are not suitable for intensive induction chemotherapy.
-
Blood: Floteuzumab saves the treatment of immunotherapy for incurable acute myeloid leukemia.
Time of Update: 2020-10-27
patients with immuno-immersive TME with PIC/ER AML, clinical benefits increased.
30 PF/ER patients treated with RP2D were treated with remission, with a CR/CRH rate of 26.7% and a total efficiency (CR/CRH/CRI) of 30.0%.
-
Take stock: A selection of Blod research on October 15, 2020.
Time of Update: 2020-10-27
: MDS/MPN Genetic Heterogeneity https://doi.org/10.1182/blood.2019004229 More than 90% of myeloid-related genes in MDS/MPN cases have somatic cell mutations, but molecular data are not currently included in the diagnostic criteria.
-
NICE UK actively recommends Sanofi's CD38 monoantigen Sarclisa for the treatment of relapsed/refractic multiple myeloma.
Time of Update: 2020-10-27
multiple myeloma (Photo: pharmaLive) The recommendation is based on data from the ICARIA-MM trial, which demonstrated that Sarclisa plus pom-dex reduced the risk of disease progression or death by 40 percent in adult patients.
-
Blood:XPR1 regulates the accumulation of plate plate plate polyphosphates to inhibit thrombosis.
Time of Update: 2020-10-27
addition, these data show that plate plate plate XPR1 is the overall regulatory factor of plateboard polyphosphate metabolism, emphasizing the basic role of phosphate stability in thrombosis.
